Gastrointestinal Diseases

Type 1 Diabetes

Type 1 diabetes (T1D) is an autoimmune disease, where the immune system attacks and destroys the cells that make the hormone insulin. Insulin is absolute necessary to control sugar levels in the blood. This means people with T1D have to rely on insulin injections to control their sugar levels all their lives.

Studies show that transplanting stem cells can help reverse diabetes, by producing cells that make insulin. Many clinical trials are underway looking at the potential of using stem cells to make beta cells, so people with T1D will no longer have to rely on insulin.

TRIAL HYPOTHESIS CLINICAL TRIAL ID
Is it safe and effective to use mesenchymal stem cells from the umbilical cord to treat type 1 diabetes? NCT01954147 Qingdao University
Will umbilical cord derived mesenchymal stem cell infusion signal beta-cells to regenerate to improve diabetic control. NCT01413035 Fuzhou General Hospital
Effectiveness of using sequential transplantation of umbilical cord stem cells and pancreatic islet cells to treat diabetes in children and adolescents. NCT01216865 Children’s Hospital of Fudan University

Type 2 Diabetes

Type 2 Diabetes (T2D) results when beta cells in the pancreas do not produce enough of the hormone insulin, which is responsible for maintaining sugar levels in the blood. Once diagnosed, this metabolic disorder is treated with medication (eg: metformin, sulfonylurea), dietary changes and exercise, based on disease severity.

Several different types of stem cells are under investigation for the treatment of T2D. Below is a list of clinical trials looking at the use of umbilical cord stem cells to treat this chronic disease.

TRIAL HYPOTHESIS CLINICAL TRIAL ID
Can umbilical cord mesenchymal stem cells be combined with standard drugs like Liraglutide to observe better outcomes with T2D? NCT01954147 Diabetes Care Center of Nanjing Military Command, Fujian, China
Safety and effectiveness of combining umbilical cord and placenta-derived mesenchymal stem cells with oral drugs used to treat T2D NCT01413035 Shandong University
Using umbilical cord mesenchymal stem cell injections to avoid the T2D complications associated with diabetic foot NCT01216865 Qingdao University

Crohn’s Disease

People with Crohn’s disease experience abdominal pain, diarrhea, fatigue, weight loss and malnutrition, because of inflammation that happens in the digestive tract. It’s one of the inflammatory bowel diseases (IBD) that is painful, debilitating and can sometimes have life-threatening complications.

There is no cure for Crohn’s and current therapies focus on reducing the symptoms. Due to their regenerative capabilities, researchers are looking at the possibility of using stem cells to ‘reset’ the immune system – to make new cells that reduce inflammation, stimulate repair and dampen the immune response that leads to the disease.

TRIAL HYPOTHESIS CLINICAL TRIAL ID
Testing the use of umbilical cord mesenchymal stem cells to treat patients with hormone controlled Crohn’s disease NCT02445547 Fuzhou General Hospital
Phase I/IIa Clinical Trials looking at safety of injecting FURESTEM-CD stem cells into patients with moderately active Crohn’s disease NCT02926300 Kang Stem Biotech Co., Ltd. Korea
Evaluating the safety and clinical benefits of autologuous hematopoietic stem cell transplantation rescue in the treatment of refractory Crohn’s disease NCT03000296 Beneficencia Portuguesa Brazil
Using human placental derived stem cells (PDA001) to treat Crohn’s disease NCT01769755 Celularity Incorporated. Warren, NJ, USA

Other Metabolic Disorders

Metabolism describes chemical reactions that happen in the body to properly breakdown nutrients. Metabolic disorders are caused when the body is unable to process metabolites either because the liver or the pancreas does not function properly or because there is an enzyme deficiency. Inherited metabolic disorders occur when a person inherits a defective gene, and can’t produce a specific enzyme.

Stem cells, hematopoietic stem cells in particular, are being explored for treating metabolic disorders.

TRIAL HYPOTHESIS CLINICAL TRIAL ID
Can MGTA-456 be used to enhance the effectiveness of umbilical cord blood transplants in patients with inherited metabolic diseases? NCT03406962 University of Minnesota
Assessing the safety of transplanting human placental-derived stem cells AND unrelated and related cord blood into patients with malignant haematological and non-malignant disorders NCT01586455 New York Medical College